Quantbot Technologies LP Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Quantbot Technologies LP acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,460 shares of the biopharmaceutical company’s stock, valued at approximately $910,000.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at $11,358,000. Lockheed Martin Investment Management Co. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $2,702,000. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $5,682,636,000. National Pension Service raised its holdings in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after purchasing an additional 82,853 shares during the period. Finally, Eurizon Capital SGR S.p.A. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $10,472,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on REGN shares. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Fifteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals Stock Down 2.3%

Shares of Regeneron Pharmaceuticals stock opened at $814.79 on Thursday. The business has a 50-day moving average of $709.88 and a 200-day moving average of $717.69. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $83.89 billion, a PE ratio of 20.14, a P/E/G ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 earnings per share. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $482,400. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.